ArticleMedicine2025
Association of Life's Crucial 9 with the risk of all-cause and cardiovascular mortality among US patients with stroke.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous studies have demonstrated an association between the Life's Crucial 9 (LC9)-based cardiovascular health score and all-cause and cardiovascular mortality in individuals without cardiovascular disease. Higher scores have been associated with reduced all-cause and cardiovascular mortality. However, no study has explored the association between the LC9 and the survival outcomes in stroke patients. This study aimed to analyze the association between the LC9 and all-cause and cardiovascular mortality in the American stroke population. Based on the National Health and Nutrition Examination Survey database from 2007 to 2018, a total of 949 eligible patients were enrolled in our cohort study. The relationship between LC9 and mortality was analyzed using univariate weighted Cox proportional regression analysis models and Kaplan-Meier curves. A subgroup analysis was conducted to ascertain whether there was an interaction between age, sex, education, hypertension, and diabetes. The restricted cubic spline curve was employed to examine the association of LC9 with risk of death. The study cohort comprised 949 patients who had experienced a stroke, of with 313 died from all causes and 89 died from cardiovascular causes. In the Cox regression model, after adjusting for confounding factors, a significant inverse association was observed between the highest third of the patients' LC9 and all-cause mortality (95% confidence interval 0.35-0.78, P = .001) and cardiovascular mortality (95% confidence interval 0.12-0.56, P < .001). Furthermore, a negative association was identified between the LC9 and patient mortality rate, indicating that the higher the LC9 score, the lower the mortality rate. The Kaplan-Meier curve showed that the higher LC9 score, the better prognosis for the patient and a reduced mortality rate. No interaction was identified in the subgroup analysis. Dose-response analysis also showed that LC9 was linearly and negatively associated with all-cause mortality and cardiovascular mortality in patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.